Latest Milestone Payments News

Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.

Aruma Resources has agreed to acquire a 90% interest in a patented mineral right at its Tillex project in Ontario, extending the interpreted copper-silver trend by 760 metres. The C$30,000 acquisition adds an untested near-term drilling target while assays from the company’s ongoing Phase 2 program remain pending.

Union Star Metals ended September with A$220,000 in cash, enough for an estimated 0.44 quarters of funding at the quarter’s outflow rate. The company has completed its Brazilian asset sale and is pursuing portfolio disposals, but permitting delays have pushed back planned drilling at its main Nevada project.

Bubalus Resources will acquire the 494-square-kilometre Skyline copper-gold project in western Tasmania, close to the Mt Lyell mine, in a deal that could reshape its exploration portfolio. Completion depends on an approximately A$2.835 million capital raising, approvals and tenure conditions.

AML3D has secured an approximately $2.2 million order from Northrop Grumman Marine Systems for a large-scale ARCEMY X metal additive manufacturing system. The contract gives AML3D its first engagement with the US defence prime and expands its contracted US base to 17 ARCEMY systems.

Dynamic Metals is reshaping its Western Australian portfolio through two gold asset sales worth up to A$4.15 million, while fresh soil sampling at Widgiemooltha creates a near-term assay catalyst. The company ended September with A$1.568 million in cash, equivalent to an estimated 2.7 quarters of funding at the reported rate of outgoings.

Carnegie Clean Energy has moved its flagship CETO wave-energy project towards offshore deployment in Spain, but the technology developer ended 2026 with a wider loss, $996,347 in cash and a material uncertainty over its ability to continue as a going concern.

Starpharma has submitted its European trial application for DEP HER2-Lu and completed manufacture of clinical material, bringing its lead radiopharmaceutical closer to first patient dosing. The biotech also took control of Petalion, collected a Radiopharm option fee and finished the quarter with AUD $34.4 million in cash.

Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.

Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.

CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.

Yari Resources has completed its Arcadia Coal Project acquisition, more than doubling its reported Queensland coal resource base to 504.9Mt. The company says resource growth has outpaced dilution, but the portfolio still carries substantial deferred obligations and development work.